Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.

Link to article at PubMed

Related Articles

Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.

Handb Exp Pharmacol. 2017;243:537-560

Authors: Sarwar CMS, Bhagat AA, Anker SD, Butler J

Abstract
Hyperkalemia can be a life-threatening disorder, especially for at-risk patients with heart failure, chronic kidney disease, with diabetes, and patients on certain drugs like renin-angiotensin-aldosterone system antagonists and mineralocorticoid receptor antagonists. There are limited therapeutic options available for hyperkalemia, and they have narrow effectiveness because of their unfavorable side effects profile in long-term and high cost utilization requiring inpatient care. Patiromersorbitex calcium and sodium zirconium cyclosilicate are novel potassium-lowering compounds for the treatment and prevention of hyperkalemia in at-risk population. These therapeutic agents have shown encouraging results in early phase II and phase III clinical trials. However, there is need to further study their efficacy and safety in heart failure population in order to establish their clinical use. The focus of this chapter will be to promote better understanding of potassium homeostasis in heart failure patients and the mechanistic overview of novel drugs, with emphasis on heart failure population.

PMID: 28382468 [PubMed - indexed for MEDLINE]

Leave a Reply

Your email address will not be published.